Clinical Trials in Italy

• Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery Recruiting
  2024-515830-34-00 Phase III Congenital antithrombin deficiency Octapharma AG
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting
  2023-505277-32-00 Phase III Diffuse Large B-Cell Lymphoma (DLBCL) AbbVie Deutschland GmbH & Co. KG
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 Phase III Severe viral lung infections Astrazeneca AB
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting
  2022-501152-28-00 Phase II Breast Cancer GBG Forschungs GmbH
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 Phase III Acute lymphoblastic leukemia Princess Maxima Center For Pediatric Oncology
• A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis Recruiting
  2022-500367-12-00 Phase III Dermatomyositis Priovant Therapeutics Inc.
• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with NMDAR or LGI1 mediated autoimm… Recruiting
  2023-504226-18-00 Phase III NMDAR or LGI1 mediated autoimmune Encephalitis F. Hoffmann-La Roche AG
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting
  2023-506548-18-00 Phase II/III Dermatitis atopic Sanofi-Aventis Recherche & Developpement
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with A… Recruiting
  2023-508349-42-00 Phase I (Other) Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR… Arrivent Biopharma Inc.
• An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting
  2023-505766-28-00 Phase II/III Hereditary angioedema Pharvaris Netherlands B.V.
• A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign… Recruiting
  2022-501374-19-00 Phase II Aggressive and Indolent B-cell Malignancies (mantle cell lym… Merck Sharp & Dohme LLC
• First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epide… Recruiting
  2023-503795-24-00 Phase I (FiH) Avanced Non-Small Cell Lung Cancer Bayer AG
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting
  2024-516066-11-00 Phase III Patients with newly diagnosed, histologically confirmed, pri… AGO Research GmbH
• Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Subcutaneously in Children With Generalized Myasthenia Gravis (AD… Recruiting
  2023-507379-23-00 Phase II/III Generalized Myasthenia Gravis Argenx
• A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab. Recruiting
  2024-513185-19-00 Phase I/II Extensive stage small cell lung cancer (ES-SCLC) Novartis Pharma AG
• The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR… Recruiting
  2024-512119-34-00 Phase II MSI-H/dMMR metastatic colorectal cancer Pfizer Inc.
• Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patie… Recruiting
  2022-501876-24-00 Phase I (Other) Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (C… F. Hoffmann-La Roche AG
• A Phase 1/2/3 Study of UX701 Gene Therapy in Adults with Wilson Disease”. Recruiting
  2022-502873-40-00 Phase I (FiH) Wilson disease Ultragenyx Pharmaceutical Inc.
• BIVV020 (SAR445088) in prevention and treatment of antibody-mediated rejection (AMR) Recruiting
  2023-509936-25-00 Phase II Transplant Rejection Sanofi-Aventis Recherche & Developpement
• Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Ki… Recruiting
  2024-515025-28-00 Phase III Pyruvate Kinase Deficiency Agios Pharmaceuticals Inc.
• A study to evaluate the effect of venglustat tablets on left ventricular mass index in male and female adult participants with Fabry disease Recruiting
  2023-509715-91-00 Phase III Fabry’s disease Sanofi-Aventis Recherche & Developpement
• A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with Aquapo… Recruiting
  2023-507817-85-00 Phase III Neuromyelitis Optica Spectrum Disorder (NMOSD) F. Hoffmann-La Roche AG
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 Phase III Adenocarcinoma of the prostate Unicancer
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting
  2023-505749-14-00 Phase III c-Met overexpressing EGFR wildtype non-squamous non-small ce… AbbVie Deutschland GmbH & Co. KG

Showing 697–720 of 3,684 trials